Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity

Palacios, Pedro Romero; Alcázar, Bernardino; Mochon, Juan Jose Diaz; Pérez, Diego; Hidalgo, Javier Luis López; Garrido-Navas, M. Carmen; Valenzuela, Florencio Quero; Lorente, José A.; Serrano, María José

doi:10.1016/j.critrevonc.2019.02.003

Cited by 17 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2d). We have termed these cells 'circulating epithelial cells' (CECs) and propose these are likely to be normal epithelial cells that enter the blood along with PV-CTCs; similar cells have recently been described in non-cancer patients 14 . In order to identify somatic mutations present in the PV-CTCs, we performed whole exome sequencing (WES) followed by targeted deep sequencing of the 3 PV-CTCs, 3 CECs and 2 WBC controls.…”

mentioning

confidence: 98%

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Chemi

Rothwell

McGranahan

et al. 2019

Nat Med

154

132

View full text Add to dashboard Cite

Data Availability Statement The majority of data generated or analysed during this study are included in this published article. The sequencing data are available through the Cancer Research UK & University College London Cancer Trials Centre for non-commercial research purposes and access will be granted upon review of a project proposal that will be evaluated by a TRACERx data access committee and entering into an appropriate data access agreement subject to any applicable ethical approvals.

show abstract

mentioning

confidence: 98%

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Chemi

Rothwell

McGranahan

et al. 2019

Nat Med

154

132

View full text Add to dashboard Cite

show abstract

“…In COPD patients, due to the chronic inflammation and the relationship between vein and alveolar epithelium, it could be conceivable that lung cells could pass in blood. In our opinion, further study will clarify the origin of these CK+ CD44v6+ cells in the blood and their role as a biomarker (85).…”

Section: High-risk Patient Monitoringmentioning

confidence: 91%

Possible role of circulating tumor cells in early detection of lung cancer

2020

View full text Add to dashboard Cite

The prognosis of lung cancer varies highly depending on the disease stage at diagnosis, from a 5-year survival rate close to 90% in stage I, to 10% or less in stage IV disease. The enhancement of early diagnosis of this malignancy is mandatory to improve prognosis, because lung cancer patients stay long asymptomatic or few symptomatic after disease onset. Nowadays, liquid biopsy has emerged as a minimallyinvasive tool to address the urgent need for real time monitoring, stratification, and personalized treatment of malignancies, including lung cancer. Liquid biopsy refers to a class of biomarkers, including circulating tumor cells (CTCs), cell-free circulating tumor DNA (ctDNA) and tumor-derived extracellular vesicles (tdEV). Since CTCs represent a crucial step in disease progression and metastasis, we reviewed here the scientific literature about the use of CTCs in early diagnosis of lung cancer; different techniques, and different strategies (e.g., source of analysis sample or high-risk groups of patients) were discussed showing the potential of implementing liquid biopsy in the clinical routine of non-metastatic lung cancer.

show abstract

“…Destruction of the lung parenchyma in COPD may result in the detachment of cells into circulation, similarly to the dissemination of circulating cancer stem cells from solid tumors. An approach to identify these circulating pulmonary cells using cytokeratin and CD44v6 markers was proposed in a study by Romero-Palacios et al in 35% of COPD patients [190]. myeloid cells (neutrophils, eosinophils, and mast cells) [176].…”

Section: Chronic Inflammatory Microenvironment Of Copdmentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer

Szalontai

Gémes

Furák

et al. 2021

JCM

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD), the frequently fatal pathology of the respiratory tract, accounts for half a billion cases globally. COPD manifests via chronic inflammatory response to irritants, frequently to tobacco smoke. The progression of COPD from early onset to advanced disease leads to the loss of the alveolar wall, pulmonary hypertension, and fibrosis of the respiratory epithelium. Here, we focus on the epidemiology, progression, and biomarkers of COPD with a particular connection to lung cancer. Dissecting the cellular and molecular players in the progression of the disease, we aim to shed light on the role of smoking, which is responsible for the disease, or at least for the more severe symptoms and worse patient outcomes. We summarize the inflammatory conditions, as well as the role of EMT and fibroblasts in establishing a cancer-prone microenvironment, i.e., the soil for ‘COPD-derived’ lung cancer. We highlight that the major health problem of COPD can be alleviated via smoking cessation, early diagnosis, and abandonment of the usage of biomass fuels on a global basis.

show abstract

Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity

Cited by 17 publications

References 30 publications

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Possible role of circulating tumor cells in early detection of lung cancer

Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer

Contact Info

Product

Resources

About